알테오젠, 바이오젠 8226억 딜…'코스닥 시총 1위' 탈환 발판 될까

Alteogen's major licensing deal with Biogen provides critical support for biotech valuation amid market skepticism over contract size expectations. The partnership validates technology credibility while raising questions about the company's over-reliance on licensing revenue and ALT-B4 product dependency, making actual revenue diversification essential for sustainable growth.